

MX₁X₂MX₃EKWDX₄NSSE

(SEQ ID NO:1),

B²
wherein X₁, X₂, X₃ and X₄ are selected from codable amino acids, or a functionally equivalent fragment of said receptor, in a substantially pure form or a host cell transformed according to claim 14, with a test agent under conditions enabling the activation of said receptor, and detecting an increase or decrease in the receptor activity.


REMARKS

The above amendments are made to delete multiple dependency in the claims. No new matter is contained in the amendment.

Please charge any fee deficiency or credit any overpayment to Deposit Account No. 50-1088.

Respectfully submitted,

CLARK & BRODY



Christopher W. Brody
Reg. No. 33,613

1750 K Street, NW, Suite 600
Washington, DC 20006
Telephone: 202-835-1753
Facsimile: 202-835-1755
Docket No.: 12020-0003
Date: December 8, 2000

MARKED-UP CLAIMS

Claim 11 (once amended) A host cell transformed with a polynucleotide molecule [according to] encoding an NPY-Y7 receptor or a functionally equivalent fragment thereof, wherein the encoded NPY-Y7 receptor is characterized by the N-terminal amino acid sequence:

MX₁X₂MX₃EKWDX₄NSSE (SEQ ID NO: 1),

wherein X₁, X₂, X₃, and X₄ are selected from codable amino acids [any one of claims to 9] or a plasmid or expression vector according to claim 10.

Claim 22 (once amended) A method for detecting agonist or antagonist agents of an NPY-Y7 receptor, comprising contacting an NPY-Y7 receptor [according to] which is characterized by the N-terminal amino acid sequence:

MX₁X₂MX₃EKWDX₄NSSE (SEQ ID NO:1),

wherein X₁, X₂, X₃ and X₄ are selected from codable amino acids, or a functionally equivalent fragment of said receptor, in a substantially pure form [any one of claims 15-19] or a host cell transformed according to claim 14 [any one of claims 11 to 14], with a test agent under conditions enabling the activation of said receptor, and detecting an increase or decrease in the receptor activity.